Eva Colas Ortega

Biografía y Trayectoria

Eva Colas, PhD in Biosciences from the Autonomous University of Barcelona (2011), has developed a strong background in gynecology research, with a particular emphasis on implementing a molecular diagnosis and advance in personalized medicine for endometrial and ovarian cancers, and endometriosis.

He currently leads the Group of Biomedical Research in Gynecology within the Vall d’Hebron Institute of Research (Barcelona). He is also a board member of the European Endometrial Cancer research network (ENITEC) and a member of the Precision Diagnostics and Therapies Program at CIBERONC (CB16/12/00328), contributing to international and nationwide collaborative efforts in translational cancer research.

Dr. Colas has extensive experience in gynaecological liquid biopsies, analyzed by mainly proteomic techniques but also a diverse variety of -omics, applied to improve diagnosis and management of gynaecological patients. As well, her group created one of the largest platforms in preclinical patient-derived models for endometrial and ovarian cancers (www.gynepdx.com), which are used to assess new treatments approaches for EC patients.

She has an H-index of 35, gathered through her published 94 scientific articles, in which she is senior author in 20 of them. Her scientific and leadership capabilities are reflected in her supervision of 14 PhD theses, two of them obtained a Pioner Award and two were Extraordinary Award of the university department. She has participated in 39 competitive research projects, serving as principal investigator in 17 of them. Among those, two are European projects. In addition to competitive research projects, Dr. Colàs has signed ten contracts with biotechnology and pharmaceutical companies. Dr. Colás stands out for her entrepreneurial spirit and her strong commitment to translating research findings into clinical practice improvements. She has filed 4 patents, and in 2021, she founded and is currently the Chief Scientific Officer of her own spin-off company, (http://www.mimark.es), whose mission is to improve women’s health through innovative solutions.

Líneas de Investigación Actuales

• Optimización de protocolos de aislamiento de ctDNA.
• Evaluación del valor pronóstico de las Células Tumorales Circulantes (CTCs).
• Desarrollo de paneles de secuenciación de nueva generación (NGS) adaptados a la biopsia líquida.
• Estudio de microvesículas y exosomas en la metástasis tumoral.

Publicaciones Destacadas

Puede consultar el listado completo en el perfil ORCID.

El Dr. Toledo ha publicado más de 50 artículos en revistas peer-reviewed, incluyendo *JAMA Oncology* y *Clinical Cancer Research*. Es revisor habitual de diversas revistas científicas internacionales y participa activamente en congresos internacionales.